Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.56 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 6/20 | 0.44 |
| ▸ | MMP3 | P08254 | 4/20 | 0.44 |
| ▸ | TACR3 | P29371 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GRN | P28799 | 1/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19435047 | 0.85 | RIPK1 (0.76) | RIPK1CYP26A1ATML3MBTL1ALDH1A1 | |
| SCHEMBL19435046 | 0.85 | RIPK1 (0.76) | RIPK1CYP26A1ATML3MBTL1ALDH1A1 | |
| SCHEMBL7820171 | 0.83 | RIPK1 (0.55) | RIPK1CYP26A1ATML3MBTL1ALDH1A1 | |
| SCHEMBL25590886 | 0.80 | RIPK1 (0.67) | RIPK1GRNSORT1 | |
| SCHEMBL20238063 | 0.77 | ALDH1A1 (0.56) | RIPK1CYP26A1ALDH1A1MMP3SMN1; SMN2 | |
| SCHEMBL20238311 | 0.77 | ALDH1A1 (0.56) | RIPK1CYP26A1ALDH1A1MMP3SMN1; SMN2 | |
| SCHEMBL8062915 | 0.77 | ALDH1A1 (0.56) | RIPK1CYP26A1ALDH1A1MMP3SMN1; SMN2 | |
| SCHEMBL1875590 | 0.76 | GRN (0.53) | RIPK1GRNSORT1MEN1KMT2A | |
| SCHEMBL19435050 | 0.75 | RIPK1 (0.64) | RIPK1L3MBTL1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL17874097 | 0.75 | RIPK1 (0.64) | RIPK1L3MBTL1ALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105567-A1 | Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity | ALLERGAN, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| EP-2185506-A1 | PYRROLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST OR ANTAGONIST BIOLOGICAL ACTIVITY | Allergan, Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009026407-A1 | PYRROLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST OR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105567-A1 | Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity | S1PR1, S1PR2, S1PR3 | RIPK1 1159/4885CYP26A1 2750/4885ATM 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.